November 2004
Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5
Trade Publication
Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.


Related Articles

  • Genentech, GlycArt and Roche sign collaboration agreement.  // PharmaWatch: Cancer;Nov2008, Vol. 7 Issue 11, p4 

    The article reports on the collaboration agreement among biotechnology company Genentech Inc., GlycArt company, and Roche Group Co.. It states that the firms plans to develop GA101, a humanized anti-CD20 monoclonal antibody that will potentially treat hematological malignancies. According to Hal...

  • Roche: buying up for biotech boost.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p14 

    The article report that Roche Holding AG has announced that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology markets. The deal promises to strengthen Roche's drug...

  • FINE CHEMICALS. Tyler, Alan // European Chemical News;10/4/2004, Vol. 81 Issue 2118, p28 

    Presents news briefs on the fine chemical industry as of October 4, 2004. License agreement between U.S.-based biotechnology company Kereos and DowPharma; Information on a joint venture company to be established in China by Mitsubishi Corp. with Junsei Chemical and a Shanghai-based fine...

  • Roche In-Licenses Galaxy Biotech's Preclinical FGF2 Antibody Programme. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 10, p130 

    The article reports that Roche has licensed international rights to the preclinical-stage antibodies of Galaxy Biotech targeting fibroblast growth factor 2 (FGF2) in cancer metastasis. It states that Roche will be responsible for the development and commercialisation of the project and will pay...

  • Roche chooses to develop Genmab antibodies.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8 

    Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.

  • Roche: buying up for biotech boost.  // PharmaWatch: Cancer;Sep2005, Vol. 4 Issue 9, p17 

    The article reports on the announcement by Roche Pharmaceutical Co. that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen...

  • Dalcetrapib.  // Drugs in R&D;2010, Vol. 10 Issue 1, p33 

    Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific...

  • MDRNA signs licensing agreement with Roche.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18 

    The article reports on the signing of a licensing agreement by MDRNA Inc. and Roche Pharmaceuticals. The licensing agreement is consistent to which Roche will get a non-exclusive license to a portion of MDRNA's technology platform for the development of ribonucleic acid interference-based...

  • Roche pulls out of alliance with Basilea for new antibiotic.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p17 

    Reports on the strategic alliance of Roche Pharmaceutical Co. with Basilea Pharmaceutica Ltd. for the development of new antibiotic drug. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for pharmaceutical biotechnology industry.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics